Email this article Treatment of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin’s lymphoma (gray zone lymphoma) in children and young adults: a case series
- Authors: Volchkov E.V.1, Senchenko M.A.1, Abramov D.S.1, Biyachuev E.R.2, Prudnikova O.N.3, Konovalov D.M.1, Myakova N.V.1
-
Affiliations:
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- S.P. Botkin City Clinical Hospital of Moscow Department of Health
- Clinical Oncological Dispensary
- Issue: Vol 21, No 1 (2022)
- Pages: 94-102
- Section: CLINICAL OBSERVATIONS
- Submitted: 29.03.2022
- Accepted: 29.03.2022
- Published: 29.03.2022
- URL: https://hemoncim.com/jour/article/view/595
- DOI: https://doi.org/10.24287/1726-1708-2022-21-1-94-102
- ID: 595
Cite item
Full Text
Abstract
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin’s lymphoma (cHL) is a rare malignant disease that develops from mature B cells. This disease was first recognized as a distinct entity in 2008. It is most common in the 20 to 40 age group and rare in children. Currently, there are no clear criteria for diagnosis and standard therapy for such patients. According to the literature, it is possible to use treatment regimens applied for both aggressive B-cell lymphomas and Hodgkin's lymphoma. The addition of anti-CD20/CD30 targeted agent to standard therapy may be effective, given the expression of these markers by tumor cells. In this article, we present the clinical and morphological characteristics of patients with unclassifiable B-cell lymphoma with features intermediate between DLBCL and cHL, diagnosed at our center, including 4 patients at the onset of the disease in childhood. Patients and/or their legal representatives have consented to the use of information, including photographs, in scientific research and publications.
About the authors
E. V. Volchkov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: volchcov.egor@yandex.ru
ORCID iD: 0000-0002-2574-1636
Egor V. Volchkov, a hematologist at the Department of Oncohematology
1 Samory Mashela St., 117997, Moscow
Russian FederationM. A. Senchenko
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-9921-5620
Moscow
Russian FederationD. S. Abramov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0003-3664-2876
Moscow
Russian FederationE. R. Biyachuev
S.P. Botkin City Clinical Hospital of Moscow Department of Health
Moscow
Russian FederationO. N. Prudnikova
Clinical Oncological Dispensary
Omsk
Russian FederationD. M. Konovalov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0001-7732-8184
Moscow
Russian FederationN. V. Myakova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-4779-1896
Moscow
Russian FederationReferences
Supplementary files
